VC
CRL icon

Veracity Capital’s Charles River Laboratories CRL Stock Holding History

Veracity Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,384
Closed -$276K – 210
2025
Q4 		$276K Sell
1,384
-344
-20% -$62.4K 0.08% 208
2025
Q3 		$270K Sell
1,728
-2,384
-58% -$379K 0.09% 206
2025
Q2 		$624K Buy
4,112
+814
+25% +$109K 0.21% 105
2025
Q1 		$496K Buy
3,298
+107
+3% +$17.9K 0.19% 119
2024
Q4 		$589K Buy
+3,191
New +$615K 0.21% 111

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Veracity Capital's CRL Position: Q1 2026 in Review

Veracity Capital sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,384 shares — an estimated $276K sold.

Veracity Capital first reported a position in CRL in Q4 2024 and held it in 5 quarters. The position peaked at $624K in Q2 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Veracity Capital reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Veracity Capital sold 1,384 Charles River Laboratories shares in Q1 2026, an estimated $276K.
  • Veracity Capital first reported a position in Charles River Laboratories in Q4 2024 and held it in 5 quarters.
  • Veracity Capital's Charles River Laboratories position peaked at $624K in Q2 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Veracity Capital's 13F filing for Q1 2026, filed 9 Apr 2026.